MSTN and sarcopenia: Several studies have indicated that antagonization of MSTN, activin A, and GDF11 signalling is a promising therapeutic approach for sarcopenia, and several smaller clinical trials have demonstrated that inhibition of MSTN/ActRII signalling may help to improve muscle mass in patients with muscle wasting [130].